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Abstract
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder associated with
mutations in TSC1 and TSC2 genes, upregulation of mammalian target of rapamycin signaling, and subsequent
tumor formation in various organs. Due to the many manifestations of TSC and their potential complications,
management requires the expertise of multiple medical disciplines. A multidisciplinary care approach is
recommended by consensus guidelines. Use of multidisciplinary teams (MDTs) has been shown to be beneficial in
treating other complex diseases, such as cancer. In a lifelong disease such as TSC, an MDT may facilitate the
transition from pediatric to adult care. However, little guidance exists in the literature regarding how to organize an
MDT in TSC.
Methods: To discuss the best approach to assembling an MDT, this project was initiated in October 2017 with a
meeting of 12 physicians from various specialties and various countries. Following this first meeting, the experts
generated statements on the most important aspects to implement in establishing an MDT for TSC by 3 rounds of
selection using a Delphi process via electronic correspondence. Finally, TSC patient advocates reviewed the findings
and provided additional insights from a patient perspective.
Results: A 3-step roadmap was recommended, starting with identifying a single individual to begin organizing care
(Step 1), then establishing a small core team (Step 2), and finally, establishing a larger multi-disciplinary team (Step
3). Because of the multisystemic nature of TSC, the MDT should include specialists such as a neurologist, a
neurosurgeon, a nephrologist, a urologist, a pulmonologist, an ophthalmologist, a cardiologist, a dermatologist, a
geneticist, and a psychiatrist/psychologist. The MDT should recommend a care plan for each patient based on the
individual’s needs and in consultation with him/her or his/her family. Some of the most important aspects of an
MDT that were agreed upon included identifying a case manager to help coordinate care, providing access to
health care professionals of varying specialties, and including a lead physician who takes medical responsibility for
patients’ overall care.
Conclusions: The results of our consensus provide guidance to support the initiation of an MDT in TSC.
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Background
Tuberous sclerosis complex (TSC) is a rare autosomal
dominant genetic disorder occurring in 1 in 6000 live
births [1, 2]. It is caused by mutations in either the
TSC1 or TSC2 gene, which result in upregulation of the
mammalian target of rapamycin (mTOR) pathway and
subsequent tumor growth in various organs such as the
brain, heart, skin, eyes, kidney, lung, and liver [2, 3].
Clinical phenotypes of TSC can vary greatly from pa-
tient to patient, ranging from milder (such as a single
manifestation of TSC) to more severe disease (such as
affecting multiple organs, developing early epilepsy and
neurodevelopmental issues) [4]. In addition, many mani-
festations of TSC have age-dependent expression [2].
These factors together can complicate evaluation and
management of TSC.
Because many manifestations can lead to complica-
tions and evolve over a patient’s lifetime, the expertise
of multiple disciplines is needed to effectively manage
patients with TSC. For example, cardiac rhabdomyo-
mas can develop prenatally and are thus one of the
earliest detectable signs of TSC [2, 5]. Although they
are usually asymptomatic and regress with age, these
lesions occasionally cause arrhythmias and lead to
ventricular dysfunction and thus may require consult-
ation with a cardiologist [2, 5]. Hypomelanotic mac-
ules on the skin can be present at birth, while other
cutaneous lesions such as facial angiofibromas and
ungual fibromas develop later in life and may require
treatment by dermatologists [2, 6]. Because skin le-
sions are prominent manifestations that can be visible
at a young age, dermatologists are also in a position
to identify TSC early in the disease course [7].
In addition, brain lesions such as cortical tubers,
subependymal nodules, and subependymal giant cell
astrocytomas, and seizures (which are frequently diffi-
cult to treat) can also develop early in a patient’s life
and may require input from neurologists, neurosur-
geons, and epileptologists [2, 5, 8]. TSC is associated
with a wide range of behavioral, psychiatric, intellec-
tual, learning, neuropsychological, and psychosocial
difficulties, which manifest in childhood and persist
throughout life. These TSC-associated neuropsychi-
atric disorders (TAND) therefore require regular
monitoring and coordination with early intervention
and educational specialists, psychologists, psychia-
trists, and social workers (childhood to adult special-
ists) [6, 9–12].
As a patient ages, cysts and angiomyolipomas can de-
velop in the kidneys, which may lead to chronic kidney
disease, and thus require the consultation of a nephrolo-
gist [2, 5]. Nephrologists may also have an important role
managing medications related to the treatment of TSC
that require additional monitoring of renal function, such
as everolimus [13, 14]. Patients with TSC are also more
likely to develop some malignancies, particularly renal cell
carcinomas and pancreatic neuroendocrine tumors, and
usually at a younger age than the general population [15–
17]. Another concern, primarily for female adolescents
and adults, is the potential development of lymphangio-
leiomyomatosis in the lungs, which, if present, requires
consultation with a pulmonologist [2, 5].
The 2012 International Tuberous Sclerosis Complex
Consensus Conference established recommendations
for the diagnosis and treatment of TSC [18, 19]. Be-
cause of the complex multisystem nature of the
disease, a multidisciplinary approach in the manage-
ment of TSC was recommended [6, 19–21]. The use
of multidisciplinary teams (MDTs) has been shown to
be beneficial in improving management and outcomes
in patients with other complex diseases [22–26]. For
example, multidisciplinary discussion is recommended
in the diagnosis of idiopathic pulmonary fibrosis [26].
In a retrospective observational study, MDT discus-
sions were responsible for the definite diagnosis in
80.5% of 938 patients with interstitial lung disease
[25]. Of these 938 patients, 455 had received a diag-
nosis from a referring physician before multidisciplin-
ary discussion, and 41.9% of those patients had their
diagnosis changed after multidisciplinary discussion
[25]. In addition, diagnosis through multidisciplinary
discussion was able to better discriminate between
idiopathic pulmonary fibrosis and other interstitial
lung diseases compared with diagnoses made before
multidisciplinary discussion [25]. In cancer, MDTs
resulted in more evidence-based medicine and more
timely treatment, and in some cases, led to improved
survival [27]. Patient-reported experience of care had
the greatest improvement for the particular cancers
for which MDTs were more established [27]. In TSC,
a multidisciplinary approach is also important in
facilitating transition of care from childhood to adult-
hood as individuals age [20, 21, 28, 29]. Young adult
patients have expressed the need for multidisciplinary
care that is well informed and easily accessible, fo-
cuses on the patient as a whole (including mental
and physical health among other factors), and
includes his/her family as they transition to adult care
[28]. Multidisciplinary care can be useful to reduce
the significant burden placed on caregivers of patients
with TSC, especially concerning the amount of health
care utilization (e.g., doctor visits, procedures, or
tests) required to treat the patient [30], as well as on
the patients themselves, although further studies are
needed to evaluate the benefits of MDT on patient
and caregivers.
Some reports have encouraged the use of specialized
TSC clinics, which may not be available for all patients
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because of cost and geography [20]. There are others
who have reported their personal experience in run-
ning an MDT clinic for TSC, including a list of prac-
titioners involved and how care in their clinic is
organized [29]. Other groups have focused on the pa-
tient concerns MDTs should consider when imple-
menting a transition of care from youth to adulthood
[28]. Still others have performed studies showing how
their use of MDT has increased rates of patient
follow-up and opportunities for exams or treatments
[31]. However, there is still a lack of published litera-
ture on how best to approach establishing an MDT.
The aim of this report is to announce the results of a
task force identifying key steps in developing an
MDT in TSC as well as the key components of the
development and function of the MDT.
Methods
A group of 12 physicians from various specialties in-
cluding neurology (pediatric and adult), psychiatry,
TAND, neurosurgery, dermatology, nephrology, and
pulmonology convened face to face in October 2017
to discuss the steps needed for organizing an MDT.
A 3-step roadmap was agreed upon to help develop
an MDT, starting with identifying a single individual
to begin organizing care, then establishing a small
core team, and finally establishing a larger multidis-
ciplinary team.
In addition to proposing steps for establishing the
MDT, the committee of physicians also discussed,
based on their expertise, the aspects of the MDT that
were most important to implement. These recommen-
dations were produced via a 3-step Delphi process
[32] led by one of the authors (SA) via online corres-
pondence. Step 1 required each member to generate a
list of 10 statements summarizing key aspects that
were important in developing an MDT. For Step 2,
all statements were collated, and members were asked
to rank statements in the overall list on a scale of 1
to 10 based on importance (1 being least important
and 10 being most important), after which the top 16
statements were identified based on those that met a
cutoff score of ≥7.5. For Step 3, the top 16 statements
were again scored from 1 to 10 by members of the
committee, based on priority of implementation (10
being the most urgent and 1 could be implemented
later). These 16 statements are discussed in detail fur-
ther below. The group also discussed the stages of
developing a TSC clinic during the formulation of the
manuscript.
Input and insight from TSC patients/patient advo-
cates regarding the committee’s findings were sought,
which included feedback on existing concepts and
additional areas of importance from the patient
perspective.
Results
Organizing a multidisciplinary care team for the
management of TSC
Three steps were identified by the task force/group
(Table 1). The authors recommend that throughout this
process, input from patients and their families, available
research, and sharing of data between specialties should
be considered in evaluating how to organize the team
(Fig. 1).
Step 1—single person
To establish the MDT, the first step is to start with a
single dedicated physician. Ideally, this physician should
be able to liaise with the family of the patient and other
physicians, nurses, and patient managers, with a shared
vision for multidisciplinary care. The physician should
connect with all specialists required for patient manage-
ment in TSC. Patient organizations can assist with iden-
tifying physicians interested in developing the MDT
team and connecting them with other physicians. An
important specialist to include at this stage is a clinical
geneticist, who can explain the results of the genetic
Table 1 Three-step process in establishing a larger multidisciplinary team
Steps Participants Main Action
Step
1
A single physician who has a passion for TSC • Treat patients with TSC
• Liaise with patient families, organizations, and other physicians
• Identify a care coordinator
• Initial drive of the MDT process
Step
2
Core team (comprising a care coordinator and members of the core medical
specialties)
• Liaise with patients/families
• Coordinate physicians for management decisions
• Organize patient follow-up and referrals
• Liaise with other centers
• Collaborate with TSC patient organization if available and able
Step
3
Full MDT and reference network with the assistance of the care coordinator • Operational MDT
MDT multidisciplinary team, TSC tuberous sclerosis complex
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analysis and provide counselling about risk of inherit-
ance. Because clinical geneticists see both children and
adults, in some cases they might be in the position to
fulfill the role of the Step 1 physician as well as care co-
ordinator of the MDT.
This initial person does not need to be a senior mem-
ber of the medical team; however, he or she should have
some experience in managing patients with TSC. In
addition, as the starting point for the team, this individ-
ual should have the energy and stamina to commit to
this endeavor and have a sense of personal ownership of
the project.
Finally, as information on TSC is ever evolving, the
physician should maintain up-to-date knowledge and be
able to attend relevant international conferences to bet-
ter understand the patient perspective and participate in
clinical research.
Step 2—small Core team
The next step to establishing the MDT is the
organization of a small core team, with the goal of
obtaining support from the core specialties. Although
there is not one set method to establishing the core
team, typically the core team should comprise one care
coordinator/nurse and one or more physicians (special-
ists). This core team ensures more continuous connec-
tion between the patients/families and the greater TSC
team. This allows for easier discussion between physi-
cians regarding the most effective decisions in manage-
ment and fosters organization of future patient
follow-ups.
The core team should help organize appropriate refer-
rals and coordinate scheduling of procedures/office visits
and be responsible for identifying contacts at other treat-
ment centers or referral sites, if needed. The core team
may further tap into reference networks for other practi-
tioners, focusing on those who specialize in rare
diseases.
Step 3—multidisciplinary team
To assemble the larger MDT, the core team should re-
cruit members from the reference network they have
established. Ideally, an MDT to manage TSC should in-
clude physicians with specialties that are required to ap-
propriately address the needs of the patients. These
specialties can include pediatrics, genetics, diagnostic
radiology, interventional radiology, cardiology, pediatric/
adult neurology, respiratory medicine, pediatric/adult
nephrology, dermatology, neurosurgery, oncology, fetal
medicine, urology, ophthalmology, psychiatry, psych-
ology, intellectual disability psychiatry, and surgery [12,
33]. At this stage, the team should reassess its way of
functioning and evaluate whether it adequately meets
the needs of the patient community on a regular basis. It
is particularly important to establish who is responsible
for soliciting this feedback (e.g., the treating physician or
nurse).
Ideally, one should begin securing a dedicated care co-
ordinator when putting together the core team; however,
a dedicated care coordinator (part-time or full-time, de-
pending on the expected size of the team) is required
when the MDT is established. Team members would
also benefit from developing leadership and manage-
ment skills in order to accommodate a plan for shared
(or to transfer) leadership as the team grows.
Most important factors in establishing the
multidisciplinary team
The 16 statements produced by the committee re-
garding the most important factors in establishing the
Fig. 1 Consensus-established roadmap for development of an MDT
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MDT can be found in Table 2, which also includes
the mean (standard deviation) score that was calcu-
lated for each item at Step 3 of the process described
above.
The panelists agreed that identifying a patient care co-
ordinator was the most important aspect of establishing
the MDT. An MDT cannot function without
organization and cooperation; thus, having a care coord-
inator allows for the MDT to perform the rest of its
functions in providing care efficiently and effectively.
Other highly important aspects of establishing an
MDT include creating a list of other health care profes-
sionals who would participate in the care of patients
with TSC within the clinic. The MDT should have a pool
of able health care professionals readily available for pa-
tient referral depending on the patient’s needs. A lead
physician who is ultimately responsible for patient care
and the organization of the clinic should be identified, as
well as core physicians in the clinic who may be needed
to provide care for the patient. The MDT should identify
and communicate with a network of local or regional
health care professionals outside of the clinic, including
primary care providers and those who treat somatic and
behavioral aspects of TSC. Due to the complexity of
managing patients with TSC, use of a hub-and-spoke
model would assist in keeping primary care physicians
involved and informed. Two-way communication be-
tween the clinic and the patient’s primary physician is of
paramount importance. In some countries the primary
physician will be a general practitioner or office general-
ist doctor, whereas in others it will be a specialist (e.g.,
pediatrician or neurologist). In addition, establishing a
schedule of patient investigation and monitoring is
important to avoid compounding the frequency of visits.
A good MDT must also create a plan to handle diag-
nosis and management of TAND-related conditions. As
the majority of patients with TSC will develop some type
of neuropsychiatric manifestations across their lifespan,
managing these manifestations is critical, especially as
TAND is a very significant burden on daily life [9, 34].
Establishing a patient database was also considered to
be beneficial to better organize patient care. The patient
database can be used for case management and discus-
sion as well as serve as a source for clinical research.
Once established, the MDT can evolve into a TSC
Center of Excellence, which is a TSC clinic that provides
care coordination, provides many services and can ac-
cess any others needed, and commits to undertake
Table 2 Top 16 most important aspects to implement in a multidisciplinary TSC team
Mean
Score
SD
1 Identification of a patient care coordinator (nurse or other professional) for duties including case management, answering
questions, direct contact with patient, triage for specialists, etc.
9.2 1.1
2 Creation of a list of health care professionals associated with the clinic involved in management of patients with TSC, including
their current email, phone number, and availability to see patients
8.7 1.6
3 Identification of a lead physician (with at least 1 or 2 deputies) who takes medical responsibility for the patients’ overall care and
managerial responsibility for organizing the clinic
8.4 1.1
4 Organization/identification of care pathway in the clinic and establishing investigation schedule according to patient age (to
avoid multiple visits to the hospital)
7.9 1.1
5 Following accepted TSC guidelines/protocol 7.7 2.4
6 Identification of a network of local or regional health care professionals outside of the clinic 7.5 1.2
7 Creation of a plan for diagnosis and management of TSC psychiatric comorbidities (e.g., TAND, autism) 7.4 2.0
8 Establishment of a patient database for case management and research 7.2 1.5
9 Creation of TSC center of excellence for complex cases 6.8 2.6
10 Creation of a plan for transition from pediatric to adult care, including specified age of transition, steps taken, and identification
of health care professionals for adult care
6.7 2.4
11 Establishment of MDT meetings that include case discussion, discussion of guidelines, logistics 6.6 1.6
12 Creation of a prenatal diagnosis program (i.e., identifying cardiac tumors) 6.5 2.7
13 Ability to perform investigation imaging such as MRI and CT under sedation (or possibly general anesthesia) 6.4 2.7
14 Establishment of a link between clinic and local patient/family TSC organizations—ideally have a representative of TSC
organization present at clinics
6.3 1.7
15 Establishment as a source for dissemination of information on TSC for patients and health care professionals, including any
appointments, reports, etc.
6.2 1.1
16 Establishment of communication with patient’s primary care physician and other family physicians to clarify responsibilities 5.9 1.6
CT computed tomography, MDT multi-disciplinary team, MRI magnetic resonance imaging, SD standard deviation, TAND TSC-associated neuropsychiatric disorder,
TSC tuberous sclerosis complex
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research by building up experience and keeping abreast
of—and ideally participating in—TSC research. Such a
center can also exchange experience with other Centers
of Excellence. These centers would preferably incorpor-
ate spaces where all specialists can be found in one
clinic, where the patient can reach each of them easily,
or provide a virtual clinic service to simplify patient
interaction with specialists. Becoming a Center of Excel-
lence in TSC is ideal, although this may not be feasible
in all facilities; nevertheless, the MDT should strive
towards this goal.
The team should create a plan for transitioning
pediatric patients to adult care. Medical issues and con-
cerns change with age and may pose challenges for
patients who transition to more adult-oriented care [6].
Ideally, the process of establishing and building an MDT
TSC clinic for adults should be underway at the same
time that clinics for children are being established, or
the same clinic should be used for both children and
adults. Transition to adult care may be especially chal-
lenging for individuals with TSC because of
TSC-associated intellectual disability and other
TAND-related issues. Therefore, the MDT for adults
must have familiarity with managing intellectual disabil-
ity and TAND.
The MDT will also benefit from holding regular meet-
ings. These meetings can increase collaboration and
promote discussion of patient cases and current guide-
lines, [18, 19] and can be used to keep team members
up to date on the progress of basic or clinical research,
and may be conducted either in the clinic or elsewhere.
In addition, meetings provide an opportunity to discuss
and align on protocols used in the clinic.
Creation of a prenatal diagnosis program is another
important function of the MDT. Cardiac rhabdomyo-
mas are a major feature of TSC and are commonly
observed in prenatal ultrasound of patients with TSC
(up to 80%) [18, 35]. In addition, brain lesions such
as cortical tubers and subependymal nodules are often
reported prenatally, and subependymal giant cell as-
trocytomas that develop in early childhood are other
early indicators of TSC [2, 8]. Prenatal diagnosis pro-
grams should also include genetic testing, not only to
confirm diagnoses but to assess the patient’s potential
phenotype [36]. Early identification of patients with
TSC offers the opportunity to provide optimal paren-
tal education on epilepsy and TAND and to initiate
early treatment and interventions with the aim of im-
proving clinical outcomes [37]. For example, early
identification and management of seizures in infants
with TSC can potentially improve cognitive outcomes
[38]. Research into useful approaches to make an
early diagnosis before seizure onset has been recently
conducted [35].
Young patients with TSC will require routine imaging
via magnetic resonance imaging (MRI), so it is important
that the MDT has the capability to perform these im-
aging studies with sedation (possibly general anesthesia
in some cases) and, where possible, they should combine
imaging studies of multiple areas, such as the brain and
abdomen using an adapted imaging protocol [19].
Patient and disease organizations can help in support-
ing patients and research. It is useful for the MDT to
establish a relationship with such organizations, prefera-
bly with a representative of a TSC organization partici-
pating in their clinics. Close collaboration with the
patient organizations throughout can be of benefit at all
stages of MDT development, including initial set-up,
growth, full expert team, and later can be helpful for
regular assessment of further needs. Patient organiza-
tions can also give complementary support such as offer-
ing social-emotional feedback, giving information on the
disease in lay-language, connecting patients with others
in similar situations, and providing a feeling of
community.
Lastly, it is important for the MDT to serve as a
source of information for patients and other health care
professionals and to communicate effectively with pa-
tients’ primary care physicians.
TSC clinic development
The development of a TSC clinic can occur in several
stages (Table 3). The primary characteristic of a TSC
clinic is that it is a service willing to take responsibility
for coordinating and ensuring access to systematic and
holistic care for patients with TSC and their families.
This includes delivering care based on established
clinical guidelines. If it is a pediatric-only clinic, an
established plan should be in place for the transition of
older pediatric patients to adult services. The clinic
should comply with good medical practice, ensuring
communication of individual patient management plans
to all appropriate parties and also disseminating know-
ledge of TSC and its management in general. Access to
MRI and computed tomography scans under sedation is
also vital, ideally combining imaging of the brain and
abdomen in a single program. In addition, all TSC
clinics and TSC centers of excellence should be aware of
laboratories in their country where genetic analyses are
performed and should be able to request these tests
when needed.
Patient perspective
The MDT provides patients with a team-based approach
to care decisions. Without the MDT, patients may end
up receiving a variety of differing medical opinions, a
very challenging sequence of regular examinations, and
medications prescribed by different specialists. Patients
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appreciate that the MDT provides them with a single
treatment plan so that medical advice is not contradict-
ory. To this end, patients emphasize the importance of
having a single care coordinator or an individual who is
responsible within the group of health care professionals.
The level of communication with the patient’s other
health care providers is also important. In addition, pa-
tients appreciate the increased organization of care that
comes with the MDT, such as combined imaging stud-
ies, and in general, prefer the holistic approach to treat-
ment that the MDT offers (education, social support,
etc.). In general, future studies should focus on assessing
the benefits of MDT on patient care, including what as-
pects of the MDT are most important and what works
best.
TAND is an especially important concern of TSC
to patients/caregivers. Although not generally life-
threatening, TAND represents the most significant
burden on daily life experienced by patients with TSC,
and as such, it has not been assessed and addressed suffi-
ciently. A committed MDT should undertake a systematic
evaluation of TAND, facilitate prevention of TANDs, and
have a plan in place for crisis intervention.
Patient organizations should have an integral role in
the formation of the MDT. There are numerous possi-
bilities for collaboration between these organizations
and the MDT, such as helping patients find the right
kind of social support, education, family support, leisure
activities, and so on. Patient organizations can also help
in finding the best clinicians with a passion for taking
care of patients with TSC.
Discussion
Based on the discussions of our multidisciplinary con-
sensus group, we agreed upon a 3-step approach as an
efficient and straightforward method for creating an
MDT. Ultimately, we recommended that the formation
of an MDT start with a single physician who has a
passion for treating patients with TSC and is eager to li-
aise with patient families, organizations, and other physi-
cians, and who can help drive the process. Second, a
core team composed of individuals essential to the func-
tioning of the clinic, such as a care coordinator and
members of the core medical specialties, should be
formed. Lastly, a full MDT can be developed by
incorporating additional specialists identified through an
established reference network with the assistance of the
care coordinator. Based on our subsequent online cor-
respondence and Delphi process, securing this care
coordinator was considered the most important aspect
of the MDT to implement. Other important factors for
the MDT to incorporate included identifying a lead
physician, the core group of physicians, and the team as-
sociated with the clinic. Informing treating physicians/
family doctors/first-line health care workers is essential
for a good patient follow-up, especially if the patient
Table 3 Stages of TSC clinic development
Stage of Clinic
Development
Services Provided
Maturity Level 1 • Care coordinator
o Schedule appointments and investigations
o First point of contact for advice
• Lead Clinician
o With TSC interest and expertise
o Created referral pathways
• Close collaboration with patient/family organizations
Maturity
Level 2
• Care provided jointly by a core group of TSC-knowledgeable physicians from relevant specialtiesa
• MDTs to review cases and agree on management plans
• Facilitate advice and care from a broader network of specialties and from a wider geographic area than the
clinic can provide
• Establish links with other TSC clinics (via MDTs or other joint meetings for peer-to-peer continuing education)
• Formalize surveillance for TAND problems, e.g., using the TAND checklist
• Use database to facilitate monitoring of patients
Maturity
Level 3
• Work with larger network of local TSC-knowledgeable specialists; within the same care provider or closely
allied care providers
• Establish and promote local and regional network of specialists and care providers; acting as expert center
providing advice and at least annual
holistic review
• Provide expertise for review of mental health and coordination of referrals for mental health problems
Maturity
Level 4
(Center of Excellence)
• All the above, plus engage with research into TSC
MDT multi-disciplinary team, TAND TSC-associated neuropsychiatric disorder, TSC tuberous sclerosis complex
aSpecialties useful in providing TSC services: pediatrics, genetics, diagnostic radiology, interventional radiology, cardiology, pediatric/adult neurology, respiratory
medicine, pediatric/adult nephrology, dermatology, neurosurgery, oncology, fetal medicine, urology, ophthalmology, psychiatry, psychology, intellectual disability
specialists, surgery
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lives relatively far from the MDT. This team should also
agree to follow established guidelines and agreed-upon
protocols and work towards establishing transition of
care as patients age [28, 29]. Others have published on
establishing an MDT and noted similar features such as
the specialists involved, a care coordinator, contact with
primary care physicians, and including a patient data-
base [29]; however, this prior report was descriptive of
their personal experience as opposed to providing
committee-based recommendations and including the
patient’s perspective as in our research.
Currently, more literature regarding the benefits
and goals of establishing a multidisciplinary care team
in TSC is needed. This report discusses the steps to
establish an MDT and our accompanying rationale.
Future studies demonstrating the benefit of MDTs
would be of value, particularly considering the bene-
fits demonstrated from previous studies evaluating
MDTs for the treatment of cancer [27]. One of the
few available studies in TSC by Fujimoto et al. de-
scribes how the implementation of a TSC board to
organize interdisciplinary management led to higher
rates of regular follow-up, opportunities for patients
to undergo examinations, opportunities for patients to
receive neurologic treatment, and mTOR inhibitor
usage compared with before the TSC board was
implemented [31]. Studies of MDTs for TSC could
also evaluate differences in treatment outcomes and
patient satisfaction. Consensus recommendations do
advocate for the efficient use of resources through the
establishment of transition clinics where both children
and adults can receive treatment. The aim of these
clinics is to reduce duplicative tests and services
while ensuring that appropriate surveillance and man-
agement are in place to prevent more costly medical
complications and reduce mortality associated with
TSC [19, 39]. Additional questions to be answered by
future studies include what value certain specialties
can add to an MDT, how they can best work with
other parts of the health system (and education and
social support system), and how they can contribute
to improving long-term health and quality of life for
patients with TSC and their families. Future studies
should also focus on how to best provide a holistic
approach to managing TSC, including such areas as
education and psychosocial support.
From the perspective of health care providers, an
MDT allows for an organized approach to tackling a
multi-faceted disease. It enables improved management
of care through establishing agreed-upon protocols, care
coordinators and other points of contact, and modes of
communication. The MDT also promotes communica-
tion between specialists to help ensure that all are aware
of the patients’ co-existing conditions and medications
and facilitates the transition from pediatric to adult care.
Furthermore, the MDT is able to organize participation
in clinical research and provide educational opportun-
ities for health care professionals within the team.
For patients and their caregivers, the MDT can ease
the burden of utilizing and coordinating care by provid-
ing a central point of contact for physician visits, im-
aging/testing, and patient/family education. For example,
the MDT can coordinate physician and imaging visits
such that for any imaging that requires sedation could
also be used for concurrent eye and dental examinations,
blood tests, or additional imaging studies (e.g., of the
brain, kidney) that may be required. In addition, the
team should be able to organize services to aid patients
regarding particular aspects of TSC management, such
as genetic counseling, transition of care services, mental
health, and social support, and even provide
on-the-scene observation, assessment, and intervention
for TAND-related issues. Finally, the team should build a
protocol that is adapted to the needs of patients with TSC,
the facilities of the center, and available resources.
Our report has several limitations. While in our initial
meeting we had planned to include patients/patient
advocates in the development of our report, they were
not included in the initial manuscript stages. However,
the patients/patient advocates who were consulted con-
tributed substantial feedback which greatly influenced
our final report. In addition, the attendees of the initial
meeting, which called for one expert for each specialty
involved in TSC management, were specialists and thus
the expertise presented comes primarily from the
specialist perspective for practical reasons. No MDT for-
mation specialists were consulted. We acknowledge that
the composition of those who participated to this Delphi
process and theoretical exercise do not necessarily repre-
sent the composition of the MDT itself and some partic-
ipants in the management of TSC were not directly
consulted. For example, while continuous and general
care is performed by general pediatricians in children,
general internal medicine in adults, general practitioners
for all ages, these general practitioners were not included
as part of the expert committee on TSC, though the co-
authors do have experience as pediatricians and internal
medicine physicians in addition to their specialties.
Other potential participants in the management of TSC
who were not consulted or discussed at length in this
report include nurses, paramedics, psychologists/behav-
ioral therapists, intellectual disabilities specialists, phys-
iotherapists, communication specialists, behavioral
therapists, and social workers. All of these care providers
may not necessarily be a formal part of the MDT but
play important roles in patient care. The authors also
point out that our suggestions do not account for
national or regional differences in care or discuss factors
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which may facilitate or limit formation of MDTs and
recommend these areas for future study.
Conclusions
The authors recommend a 3-step approach to building
an MDT, starting with a single dedicated individual to
begin organizing care, expanding to the development of
a core team, and finally, establishing a full MDT. The
authors recommend implementation of certain key as-
pects to create an effective MDT—most importantly,
identifying a case manager to help coordinate care, pro-
viding access to health care professionals from a number
of specialties, and including a lead physician who takes
medical responsibility for the patients’ overall care.
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